RecruitingAlzheimer s Disease

An Open Label Dose Escalation Study of VY1706 in Participants With Early Alzheimer's Disease

Eligible age

30–80 yrs

Accepts

All genders

Locations

1 state

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

VY1706 first in human study in early Alzheimer's Disease is a multicenter dose escalation study

Sponsor: Voyager Therapeutics

✓ Male or female participants aged 55 to 80 years (inclusive) at Screening or aged 30 to 80 years (inclusive) if presence of a historically documented dominantly inherited mutation associated with monogenic AD.
✓ Clinical diagnosis of mild cognitive impairment (MCI) due to AD or mild AD with MMSE 18-30 and CDR Global score of 0.5-1.
✓ Evidence of amyloid and tau pathology consistent with AD diagnosis by both:
✓ Apart from the clinical diagnosis of early AD, participant must be in good health as determined by the Investigator.
✓ If the participant is receiving an approved symptomatic AD treatment, such as acetylcholinesterase or NMDA inhibitors, the participant must be on a stable dose for at least 8 weeks prior to Screening and until Day 1.
✓ Stable doses of all other (non-AD-related) concomitant medications for at least 4 weeks prior to Screening and until Day 1.
✓ Must have an identified reliable Study Partner.

✕ Any medical or neurological/neurodegenerative or psychiatric condition (other than AD) that may be a contributing cause to cognitive impairment or could confound interpretation of drug effect, affect study assessments, or affect participant's ability to participate and complete the study or lead to safety concerns.
✕ Seropositive for anti-AAV9 antibodies at Screening.
✕ History of transient ischemic attack or stroke or any unexplained loss of consciousness within 1 year prior to Screening.
✕ History of seizures within 10 years prior to Screening or history of epileptic syndrome (except for history of febrile seizures in childhood).
✕ Presence of a clinically significant uncontrolled medical disorder that may compromise the participant's safety or their ability to complete all of the study assessments.
✕ History of significant cardiovascular disease.
✕ Contraindications to lumbar puncture, MRI imaging, PET imaging or corticosteroids.
✕ History of, or positive test result for human immunodeficiency virus (HIV), hepatitis C or current acute hepatitis B.

Maitland

Source: ClinicalTrials.gov · NCT07764146 · last updated 2026-09-04